AdAlta Ltd. AI Stock Analysis
Want to see AU:1AD full AI Analyst Report?
AdAlta Ltd. (1AD) AI Stock Analysis
AdAlta Ltd.
(ASX:1AD)
The overall score is at the minimum, reflecting a company in severe distress. The complete loss of revenue and ongoing cash burn are the most significant risks, leaving the company in a precarious financial position. The cleaned-up balance sheet is a minor positive but is overshadowed by the lack of income and minimal asset base. The absence of technical data and negative valuation metrics reinforce the critical risk profile.
AdAlta Ltd. (1AD) vs. iShares MSCI Australia ETF (EWA)
Not enough price history over this period.
- Market Cap
- AUD 1.52M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.9
- Beta (1Y)
- 0.98
- Revenue Growth
- ―
- EPS Growth
- 62.90%
- Country
- Australia
- Employees
- 2
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Biotechnology
AdAlta Ltd. Business Overview & Revenue Model
Company Description
AdAlta Limited is an Australian-based clinical-stage biotechnology company dedicated to the discovery and development of innovative protein therapeutics. Its leading investigational i-body drug candidate, AD-214, is presently in Phase I clinical tria...
How the Company Makes Money
null
AdAlta Ltd. Financial Statement Overview
Summary
Financial health is critically weak. Revenue has collapsed to zero, net losses persist, and cash burn continues despite a reduced rate. The cleaned-up balance sheet with zero debt is the only positive, but minimal assets and equity provide no buffer against ongoing losses.
Income Statement
8Very NegativeBalance Sheet
30NegativeCash Flow
25Negative| Breakdown | TTM | Jun 2026 | Jun 2025 | Jun 2024 | Jun 2023 | Jun 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 0 | 0 | 677.01K | 1.74M | 3.47M | 2.75M |
| Gross Profit | 0 | 0 | 457.50K | 1.51M | 3.44M | 2.49M |
| EBITDA | -4.80M | -4.80M | -4.38M | -5.26M | -7.58M | -7.31M |
| Net Income | -4.68M | -4.68M | -4.50M | -5.38M | -4.85M | -6.06M |
Balance Sheet | ||||||
| Total Assets | 1.72M | 1.72M | 2.14M | 5.57M | 7.73M | 10.65M |
| Cash, Cash Equivalents and Short-Term Investments | 1.28M | 1.28M | 1.31M | 3.13M | 4.79M | 8.66M |
| Total Debt | 0 | 0 | 1.77M | 2.70M | 4.01M | 4.00M |
| Total Liabilities | 1.35M | 1.35M | 2.74M | 3.54M | 5.82M | 5.27M |
| Stockholders Equity | 370.17K | 370.17K | -598.24K | 2.03M | 1.91M | 5.38M |
Cash Flow | ||||||
| Free Cash Flow | -4.44M | -4.44M | -2.94M | -5.32M | -5.13M | -4.11M |
| Operating Cash Flow | -4.44M | -4.44M | -2.94M | -5.26M | -5.13M | -4.09M |
| Investing Cash Flow | 0 | 0 | 109.61K | -62.40K | -2,126 | -25.23K |
| Financing Cash Flow | 4.42M | 4.42M | 999.06K | 3.67M | 1.27M | 7.02M |
AdAlta Ltd. Peers Comparison
Overall Rating
AU:NEU76Outperform
AU:IMM50Neutral
AU:RCE46Neutral
AU:CMB39Underperform
AU:1AD37Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| 76Outperform | AUD 2.79B | 133.99 | 6.03% | 0.68% | -68.00% | -86.31% | |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| 50Neutral | AUD 38.33M | -0.47 | -98.86% | ― | ― | -27.73% | |
| 46Neutral | AUD 114.72M | -7.33 | 84.67% | ― | ― | 42.51% | |
| 39Underperform | AUD 10.30M | -1.39 | -247.44% | ― | -4.24% | 33.39% | |
| 37Underperform | AUD 6.42M | -0.87 | -6182.61% | ― | ― | 62.90% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:1AD | AdAlta Ltd. | ― | ― | ― | |
| AU:NEU | Neuren Pharmaceuticals Limited | 22.01 | 3.99 | 22.16% | |
| AU:IMM | Immutep Ltd | 0.03 | -0.23 | -90.00% | |
| AU:CMB | Regeneus Ltd. | 0.35 | -0.17 | -32.69% | |
| AU:RCE | Recce Pharmaceuticals Ltd. | 0.38 | -0.05 | -11.76% |
AdAlta Ltd. Corporate Events
AdAlta updates ASX corporate governance disclosures for 2026
AdAlta has lodged its updated corporate governance statement for the year ended 30 June 2026, confirming that the document is available on its website and has been approved by the board as at 20 August 2026. The company’s accompanying Appendix 4G fil...
AdAlta Releases Annual Report for Year Ended 30 June 2026
AdAlta Limited has released its annual report for the year ended 30 June 2026, outlining its corporate directory, directors’ report, financial statements, and auditor’s report. The document provides a comprehensive overview of the company’s governanc...
AdAlta posts wider annual loss and flags going concern uncertainty
AdAlta Limited reported a net loss after tax of $4.68 million for the year ended 30 June 2026, a 4% increase on the prior year’s $4.50 million loss, and did not declare any dividends for the period. Net tangible assets per share improved to $0.01 fro...
AdAlta outlines global immunotherapy ambitions while flagging investment risks
AdAlta Limited has released an investor presentation outlining its strategy to commercialise life-saving cellular immunotherapies under an “East to West” approach, signalling ambitions to translate its research into marketed therapies across multiple...
AdAlta’s EW-001 CAR-T Shows Promising Survival and Response in Advanced Mesothelioma
AdAlta reported that all five mesothelioma patients who remained on its Chinese investigator-initiated trial as of March 2026 were still alive and on study in July, extending evidence of sustained survival. Among 10 patients treated at higher EW-001...
AdAlta Posts Landmark Long-Term Responses in Mesothelioma CAR-T Trial
AdAlta has reported a major clinical milestone in its ongoing investigator-initiated trial of EW-001 in advanced mesothelioma, with the first patient to achieve complete tumour clearance remaining alive and cancer-free two years after a single dose....
AdAlta Advances EW-001 CAR-T Program and AI-Driven East-to-West Strategy
AdAlta has strengthened its position in solid tumour cell therapies by completing its initial US$1 million milestone investment in EW-001, securing rights to develop the CAR-T treatment outside Greater China and obtaining key clinical and manufacturi...
AdAlta Seeks ASX Quotation for Major New Share and Option Issue
AdAlta Limited has applied for quotation on the ASX of 37,500,000 new ordinary fully paid shares and 168,750,000 options expiring in June 2028. The issuance, lodged under an Appendix 2A, significantly increases the company’s quoted securities base an...
AdAlta Seeks ASX Quotation for Nearly 265 Million New Securities
AdAlta Ltd. has applied to the ASX for quotation of 198,750,012 new ordinary fully paid shares and 66,250,001 options expiring in June 2028, all issued on 2 July 2026. The move significantly increases the company’s listed securities base, signalling...
AdAlta expands AI-driven drug development with Oktopi collaboration
AdAlta Limited has entered a strategic collaboration with Oktopi to deploy its AI-enabled, software-as-a-service knowledge platform across AdAlta’s medicine development programs, enhancing how the company plans research, identifies critical questions...
AdAlta Issues 319.9 Million New Shares in Private Placement
AdAlta Limited has issued 319,937,238 new fully paid ordinary shares at $0.004 each to sophisticated investors under a private placement previously announced to the market. The company has lodged an application for quotation of these shares and confi...
AdAlta seeks ASX quotation for major new share and option issue
AdAlta Ltd. has applied to the ASX for quotation of 319,937,238 ordinary fully paid shares under code 1AD and 142,083,332 options expiring 3 June 2028 under code 1ADO, with an issue date of 25 June 2026. The large volume of new shares and options bei...
AdAlta targets sophisticated investors with speculative ASX-listed options offer
AdAlta Limited has issued a target market determination for a new series of quoted options, each allowing holders to acquire one fully paid ordinary share, to be offered under a prospectus dated 22 May 2026. The options, aimed at sophisticated and pr...
AdAlta files prospectus for options linked to A$2.5m placement to fund solid cancer immunotherapy push
AdAlta Limited, a Melbourne-based clinical-stage biotech, specialises in cellular immunotherapies for solid tumours and leverages an ‘East to West’ model that links Asian T cell therapy innovation with Western regulatory and commercial pathways. Its...
AdAlta hires cell therapy specialists to steer FDA path for mesothelioma CAR-T
AdAlta has engaged specialist consultancy Dark Horse Consulting Group to guide regulatory interactions with the US Food and Drug Administration for its lead CAR-T therapy, BZDS1901, as it prepares for an Australian Phase 1 clinical trial. The move ai...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 22, 2026
